Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
The Lancet (2015) - Comments
pubmed: 26414968  doi: 10.1016/s0140-6736(15)00257-3  issn: 1474-547x  issn: 0140-6736 

Bryan Williams, Thomas M MacDonald, Steve Morant, David J Webb, Peter Sever, Gordon McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Jackie Salsbury, Isla Mackenzie, Sandosh Padmanabhan, Morris J Brown,